

# Caroline Papeix

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7695241/publications.pdf>

Version: 2024-02-01

31  
papers

802  
citations

759233

12  
h-index

501196

28  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1153  
citing authors

#	ARTICLE	IF	CITATIONS
1	High doses of biotin in chronic progressive multiple sclerosis: A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 159-169.	2.0	191
2	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	7.2	115
3	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. <i>Journal of Autoimmunity</i> , 2017, 79, 84-90.	6.5	67
4	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. <i>Neurology</i> , 2020, 94, e1645-e1656.	1.1	66
5	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	3.6	47
6	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	3.0	37
7	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	7.2	30
8	Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102482.	2.0	28
9	The long-term outcome of MOGAD: An observational national cohort study of 61 patients. <i>European Journal of Neurology</i> , 2021, 28, 1659-1664.	3.3	26
10	Fast multiple sclerosis progression in North Africans. <i>Neurology</i> , 2017, 88, 1218-1225.	1.1	24
11	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2025-2037.	3.7	20
12	Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies. <i>Neurology</i> , 2015, 85, 1630-1632.	1.1	14
13	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020, 17, 128.	7.2	13
14	Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e23-e33.	1.1	13
15	Natalizumab-PML survivors with subsequent MS treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e346.	6.0	12
16	Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560886.	1.0	11
17	Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. <i>European Radiology</i> , 2021, 31, 2944-2955.	4.5	10
18	Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center. <i>Frontiers in Neurology</i> , 2017, 8, 183.	2.4	9

#	ARTICLE	IF	CITATIONS
19	Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	9
20	COVID-19 infection in NMO/SD patients: a French survey. <i>Journal of Neurology</i> , 2021, 268, 1188-1190.	3.6	9
21	Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2280-2283.	3.0	9
22	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021, 28, 2026-2036.	3.3	8
23	Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1794-1798.	3.0	7
24	Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102981.	2.0	7
25	Extensive white matter lesions after 2â€‰years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 614-616.	3.0	5
26	Fatigue evaluation in fingolimod treated patients: An observational study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 8-11.	2.0	5
27	Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination. <i>Journal of Neurology</i> , 2022, 269, 5647-5650.	3.6	5
28	False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin. <i>Multiple Sclerosis Journal</i> , 2020, 26, 257-258.	3.0	2
29	Integrated multidisciplinary clinics should be the gold standard in managing progressive MS â€œ NO. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1128-1130.	3.0	1
30	Early radiological features of severe longitudinally extensive transverse myelitis over time. <i>Journal of the Neurological Sciences</i> , 2019, 400, 7-9.	0.6	1
31	Unexpected REM sleep excess associated with a pontine lesion in multiple sclerosis. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 1117-1119.	2.6	1